US5739309A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
Assignee: Gen Probe Inc
•
Filing: 1995-05-30
•
Granted: 1998-04-14
•
Expires: 2015-05-30
Abstract
Abstract The invention features the use of a purified first targeted oligonucleotide in combination with either 1) a subtargeted oligonucleotide, 2) second targeted oligonucleotide, or 3) a non-targeted phosphorothioate oligonucleotide, to inhibit protein production of a targeted nucleic acid sequence, cell proliferation, and/or the multiplication of a foreign organism. The subtargeted oligonucleotide contains a truncated version of the targeted oligonucleotide.
Inventors
- 👤 Nanibhushan Dattagupta
- 👤 C. Nagaraja Sridhar
- 👤 Daniel L. Kacian
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 08:44
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; C12N15/1132; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/312; C12N2310/3125; C12N2310/315
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
52 words
A composition for inhibiting HIV replication comprising a targeted oligonucleotide 9 to 100 nucleotides in length comprising at least 9 contiguous nucleotides perfectly complementary to the HIV nucleic acid SEQ. ID. NO- 5: CCCGAGGGGA CCCGACAGGC CCGAAG and a subtargeted oligonucleotide consisting of the nucleotide sequence of SEQ. ID. NO. 3: GCCTGTCGGG TCCC.
Claim 2
Dependent Claim
52 words
A composition for inhibiting HIV replication comprising a targeted oligonucleotide 9 to 100 nucleotides in length comprising at least 9 contiguous nucleotides perfectly complementary to the HIV nucleic acid SEQ. ID. NO- 5: CCCGAGGGGA CCCGACAGGC CCGAAG and a subtargeted oligonucleotide consisting of the nucleotide sequence of SEQ. ID. NO. 3: GCCTGTCGGG TCCC.
Claim 3
Dependent Claim
22 words
The composition of claim 1, wherein said targeted oligonucleotide consists of the nucleotide sequence of SEQ. ID. NO. 1: CTTCGGGCCT GTCGGGTCCC CTCGGG.
Claim 4
Dependent Claim
19 words
The composition of claim 2, wherein said subtargeted oligonucleotide or said targeted oligonucleotide comprises at least one phosphorothioate linkage.
Claim 5
Dependent Claim
17 words
The composition of claim 2, wherein said subtargeted oligonucleotide and said targeted oligonucleotide are each completely phosphorothioated.
Claim 6
Dependent Claim
102 words
A composition which inhibits the multiplication of a human immunodeficiency virus comprising: a) a targeted oligonucleotide of from 9 to 100 nucleotide bases in length which will bind to nucleic acid of said human immunodeficiency virus in such a manner that it overlaps a region of said nucleic acid consisting of the nucleotide base sequence SEQ ID NO: 5 by one or more bases, and b) a subtargeted oligonucleotide consisting of a nucleotide base sequence which is a truncated version of said targeted oligonucleotide at least 7 bases in length, wherein said targeted and said subtargeted oligonucleotides are each optionally chemically modified.
Claim 7
Dependent Claim
102 words
A composition which inhibits the multiplication of a human immunodeficiency virus comprising: a) a targeted oligonucleotide of from 9 to 100 nucleotide bases in length which will bind to nucleic acid of said human immunodeficiency virus in such a manner that it overlaps a region of said nucleic acid consisting of the nucleotide base sequence SEQ ID NO: 5 by one or more bases, and b) a subtargeted oligonucleotide consisting of a nucleotide base sequence which is a truncated version of said targeted oligonucleotide at least 7 bases in length, wherein said targeted and said subtargeted oligonucleotides are each optionally chemically modified.
Claim 8
Dependent Claim
46 words
The composition of claim 5, wherein said targeted oligonucleotide comprises an least 9 contiguous nucleotide bases complementary to SEQ ID NO 5, and said Subtargeted nucleotide base sequence is a truncated version of said at least 9 contiguous nucleotide bases complementary to SEQ ID NO 5.
Claim 9
Dependent Claim
29 words
The composition of claim 6, wherein said subtargeted oligonucleotide is 40% to 60% the size of said at least 9 contiguous nucleotide bases complementary to SEQ ID NO 5.
Claim 10
Dependent Claim
17 words
The composition of claim 5, wherein said subtargeted oligonucleotide and said targeted oligonucleotide are each completely phosphorothioated.
Claim 11
Dependent Claim
17 words
The composition of claim 6, wherein said subtargeted oligonucleotide and said targeted oligonucleotide are each completely phosphorothioated.
Claim 12
Dependent Claim
17 words
The composition of claim 7, wherein said subtargeted oligonucleotide and said targeted oligonucleotide are each completely phosphorothioated.
References Cited (Backward Citations)
US5023243A
Cited
US4851330A
Cited
US4689320A
Cited
US5208149A
Cited
US5190931A
Cited
US4806463A
Cited
US5264423A
Cited
EP0288163A2
Cited
US5110802A
Cited
EP0309230A2
Cited
WO1989002896A1
Cited
US5030557A
Cited
US5252723A
Cited
WO1991015580A1
Cited
US5166195A
Cited
WO1991018004A1
Cited
WO1992007864A1
Cited
WO1992014843A1
Cited
WO1993015194A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-04-13 | 2001-10-13 | 2002-04-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-04-13 | 2005-10-13 | 2006-04-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-04-13 | 2009-10-13 | 2010-04-14 | $7700.00 | Window Closed / Lapsed |